Circulogene is excited to announce the launch of our improved Somatic NGS & Molecular Test.
We have enhanced the performance of the assay by increasing the number of DNA biomarkers, removing unused RNA biomarkers, adding Tumor Mutational Burden, and removing the need for an ice pack.
All this while we keep our commitment to you and your patient with a fast turn around time.
486 DNA Biomarkers and Tumor Mutational Burden
Tumor mutational burden is a genetic characteristic of tumorous tissue that can be informative to cancer research and treatment. It is defined as the number of non-inherited mutations per million bases of investigated genomic sequence, and its measurement has been enabled by next generation sequencing.
TumorClear (NGS panel)
The TumorClear NGS panel provides the oncologist with a molecular profile to prescribe targeted patient treatment at time of diagnosis, to understand the patient’s response to treatment, and/or molecular insight should symptomatic or radiographic concern indicate retesting.
The best-in-class report enables the oncologist to quickly and easily understand the actionable markers and mutations.
